Viewing Study NCT01401166


Ignite Creation Date: 2025-12-24 @ 4:40 PM
Ignite Modification Date: 2025-12-27 @ 6:31 PM
Study NCT ID: NCT01401166
Status: COMPLETED
Last Update Posted: 2017-03-06
First Post: 2011-07-22
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Participant Preference of Subcutaneous (SC) Versus Intravenous (IV) Herceptin (Trastuzumab) in Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer
Sponsor: Hoffmann-La Roche
Organization: